Global Human Microbiome Market Size, Segmentation, Trends and Growth Analysis Forecast by 2030

Human Microbiome Market Overview and Analysis:

The Human Microbiome is currently valued at USD 380 million in 2022, the human microbiome market is poised for substantial growth with a projected compound annual growth rate (CAGR) of 23.8% throughout the forecast period, 2023-2030.

The human microbiome refers to the collection of microorganisms, including bacteria, viruses, fungi, and other microbes, that inhabit various parts of the human body, both externally and internally. These microorganisms exist in and on the skin, in the mouth, respiratory tract, and particularly in the gastrointestinal (GI) tract, which harbors a significant and diverse microbial community.

The advances in sequencing methods and analytical techniques are driving progress in microbiome research. The integration of cutting-edge technologies enables more accurate and comprehensive analysis of microbiome data, facilitating the identification of novel insights and potential therapeutic targets. The identification of associations between dysbiosis and the development of various chronic conditions, including Clostridium difficile infections (CDIs), Crohn's disease, irritable bowel disease, ulcerative colitis, and diabetes, is a significant driver. This knowledge is spurring the development of microbiome-targeted therapies for specific medical indications. Thus, the above-mentioned factors are expected to witness significant growth over the forecast period.

Human Microbiome Market Latest Trends:

The rising interest among researchers in human microbiomes, particularly their association with respiratory diseases and immunity, is driving increased investment in research and development activities. Advancements in sequencing methods and analytical techniques are contributing to a deeper understanding of the microbiome's role in health and disease. The concept of microbiome-based therapeutics is gaining traction within the medical science community. Ongoing research efforts are focused on developing targeted interventions and treatment options for a broad spectrum of medical conditions, leveraging the manipulation of the microbiome.

Market Segmentation: The Human Microbiome Market is segmented by Type of Product (Probiotic Drugs and Other Drugs), Target Indication (Colorectal Cancer, Diabetes Mellitus, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Graft Versus Host Disease, Necrotizing Enterocolitis, Primary Hyperoxaluria and recurrent CDI), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Drivers:

The Rise in the Prevalence of Diseases

The rise in the prevalence of diseases and the exploration of the human microbiome are two interconnected areas of research that have gained considerable attention in recent years. The human microbiome refers to the trillions of microorganisms, including bacteria, viruses, fungi, and other microbes, that inhabit various parts of the human body, such as the skin, gut, mouth, and other mucosal surfaces. These microorganisms play a crucial role in maintaining human health by contributing to digestion, nutrient absorption, and immune system function. However, disruptions in the balance of the human microbiome, a condition known as dysbiosis, have been linked to various health issues. Factors such as antibiotic use, dietary changes, and lifestyle modifications can influence the composition and diversity of the microbiome, potentially leading to an increased susceptibility to diseases. Thus, the the rise in the prevalence of diseases and the exploration of the human microbiome are intricately linked. Understanding the role of the microbiome in health and disease is opening new possibilities for therapeutic interventions and preventive strategies. As research in this field progresses, it holds the potential to revolutionize healthcare by providing more personalized and effective approaches to disease prevention and treatment. The above-mentioned factors are expected to drive the growth of the studied market.

Government Investments on Healthcare Infrastructure

Investments in both healthcare infrastructure and human microbiome research complement each other. A well-equipped healthcare system enables the integration of microbiome-based diagnostics and therapies into routine medical practices. Simultaneously, advancements in microbiome research contribute to a deeper understanding of the factors influencing health and disease, informing more effective healthcare strategies. Moreover, government funding plays a crucial role in supporting basic research focused on understanding the human microbiome. This includes studying the composition, function, and dynamics of microbial communities in different parts of the body and their impact on human health. Thus, the above-mentioned factors are expected to drive the growth of the studied market.

Market Restraints:

Lack Of Favourable Reimbursement Scenario And Technology Penetration In The Developing Economies

The global microbiome market, which encompasses research, diagnostics, and therapeutics related to the human microbiome, has witnessed significant advancements in recent years. However, the growth of this market is not uniform across all regions, with developing economies facing challenges related to reimbursement scenarios and technology penetration.

Moreover, the absence of well-established reimbursement policies for microbiome-related diagnostics and therapeutics hinders market growth. Without clear reimbursement pathways, healthcare providers may be hesitant to adopt these interventions, limiting patient access and the overall market potential. Thus, such factors are expected to slow down the growth of the studied market.

COVID-19 Impact on Human Microbiome Market

The human microbiome market has experienced limited impact from COVID-19, with researchers increasingly focusing on human microbiomes due to their association with various respiratory diseases and immune responses. However, the pandemic has disrupted many research and development activities, negatively affecting this market. The easing of restrictions is expected to benefit the market, as seen in the example of Seres Therapeutics, Inc. In July 2021, the company partnered with Nestlé Health Science to jointly commercialize SER-109 in the United States and Canada, aiming to pave the way for innovative treatment modalities.

Segmental Analysis:

Probiotic Drugs Segment is Expected to Witness Significant Growth Over the Forecast Period

Probiotic drugs and the human microbiome are closely intertwined subjects that have gained considerable attention in the fields of medicine and research. Probiotics are live microorganisms, primarily bacteria and yeast, which confer health benefits to the host when consumed in adequate amounts. The human microbiome, on the other hand, refers to the diverse community of microorganisms residing in various parts of the human body, such as the gut, skin, mouth, and other mucosal surfaces. Probiotics can influence the immune system by promoting a balanced immune response. They may enhance the activity of immune cells and modulate inflammation, contributing to the prevention or management of immune-related conditions. Thus, owing to such advantnges the segment is expected to witness significant growth over the forecast period.

Inflammatory Bowel Disease Segment is Expected to Witness Significant Growth Over the Forecast Period

Inflammatory Bowel Disease encompasses conditions such as Crohn's disease and ulcerative colitis, both of which involve chronic inflammation of the gastrointestinal tract. The human microbiome, which consists of trillions of microorganisms residing in the gut, plays a crucial role in maintaining intestinal health and modulating the immune system. The gut microbiome plays a crucial role in educating and regulating the mucosal immune system. In individuals with IBD, the immune system may react abnormally to the gut microbiota, leading to chronic inflammation. Moreover, probiotics, which are live microorganisms with potential health benefits, and microbiome-based therapies are being investigated as potential interventions for IBD. The goal is to restore a healthy microbial balance and modulate the immune response to alleviate inflammation. Thus, owing to such advantages, the segment is expected to witness significant growth over the forecast period.

North America Region is Expected to Witness Significant Growth Over the Forecast Period

North America, comprising the United States, Canada, and Mexico, has been at the forefront of research and advancements in the field of human microbiome studies. The exploration of the human microbiome in North America has contributed significantly to our understanding of its role in health and disease.

Furthermore, North America is home to some of the world's leading research institutions dedicated to microbiome studies. Institutions such as the Broad Institute, the National Institutes of Health (NIH) in the United States, and various universities across the region have played pivotal roles in advancing microbiome research. The region has witnessed significant investment in microbiome-related ventures. Collaborations between academic institutions, biotech companies, and pharmaceutical entities contribute to the translation of microbiome research findings into practical applications. Thus, North America has played a pivotal role in advancing our understanding of the human microbiome, from foundational research to the translation of discoveries into clinical applications and commercial ventures. The region's commitment to innovative research, collaboration, and the integration of microbiome science into healthcare practices positions it at the forefront of this rapidly evolving field.

Human Microbiome Market Competitive Landscape:

The Human Microbiome Market is highly fragmented due to the presence of many major players working globally and regionally. Some of the major players working in this market are:

• ENTEROME (France)
• Yakult (US)
• DuPont (US)
• Metabiomics Corporation (US)
• ViThera Pharmaceuticals, Inc. (US)
• Second Genome Inc. (US)
• MICROBIOME THERAPEUTICS LLC (US)
• Vedanta Biosciences, Inc. (US)

Recent Development:

1) In July 2023, Infant Bacterial Therapeutics received orphan drug designation for its IBP-1016 bacterial product, treating infants suffering from gastroschisis, from the US FDA.

2) In July 2023, MaaT Pharma announced the publication of clinical trial results for MaaT013, a faecal microbiota derived therapeutic, targeting acute Graft-versus-Host Disease (aGvHD).

Frequently Asked Questions (FAQ) :

Q1. What is the current Human Microbiome Market size?

Q2. What is the Growth Rate of the Human Microbiome Market?

Q3. Which Region is expected to hold the highest Market share?

Q4. Who are the key players in Human Microbiome Market?